One emerging feature of the public and not-so-public policy discussion in advance of the formation of the National Medicines Policy working group is emerging stakeholder alignment that Australia's evaluation processes will need to be reformed for cell and gene therapies.
Latest Video
New Stories
-
If coercion and retribution are bad for supermarket customers, they must be bad for patients
April 18, 2024 - - Latest News -
AbbVie announces the appointment of new Australia-NZ human resources director
April 18, 2024 - - BioPharma -
'Under Karen’s leadership our local business has thrived both commercially and culturally'
April 18, 2024 - - Latest News -
Retail leader's surprise at the size of revenue revealed by Chemist Warehouse
April 17, 2024 - - Latest News -
Longstanding health sector leader and advocate steps down after 24 years
April 17, 2024 - - Latest News -
'We celebrate our 60th anniversary in Australia, I am extremely optimistic about the next 60'
April 17, 2024 - - Latest News -
Ex-AusBiotech CEO appointed to lead peak body for manufacturing technology sector
April 16, 2024 - - Latest News